DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Business Affairs Homepage

Veritas Capital, Evergreen Coast Capital to take athenahealth for $5.7 billion Gives athenahealth stock holders $135 in cash per share

A look into the medical device design process Go behind the scenes to see what factors contribute to the design of new medical devices

How hassle maps can improve radiology department operations Tips for finding and addressing friction points and improving overall patient care in radiology

Dr. Jonathan Luchs Premier Radiology Services appoints chief medical officer

When radiologists speak up, follow-up imaging improves Study supports better communication between radiologists and referring clinicians

Deborah Conrad Grand Rounds hires former Intel CMO as chief marketing officer

Siemens Healthineers' imaging business 'super-strong' says Montag Atellica lab diagnostic solutions sales also performed well

Philips to open new center of excellence in Cleveland Bringing CT, molecular imaging R&D in its latest investment in the city

Manchester United puts Canon imaging solutions into team health center The club's Aon medical center gets CT, MR and ultrasound systems

Radiology Partners scales reach with close to 30 additional sites Servicing 750 clients across 17 states

DaVita hit with $383.5 million jury verdict in dialysis death suit

by Thomas Dworetzky , Contributing Reporter
A Denver jury has dropped a mile-high $383.5 million verdict on GranuFlo dialysis maker DaVita over the deaths of three patients who suffered cardiac arrests after getting GranuFlo dialysis therapy at DaVita clinics.

The families of the three deceased patients – Irma Menchaca, Gary Saldana and Deborah Hardin – were awarded $125 million in punitive damages and compensatory damages from $1.5 million to $5 million, according to a statement by firms representing the families of the patients, Hagens Berman and Paynter Law Firm.

Story Continues Below Advertisement

Dunlee announces the relaunch of DA135 CT/e, DA165NP and Akron tubes

Dunlee announces the return of the DA135 CT/e, DA165NP, S532B and S532Q(known as the Akron tubes) CT Replacement tubes, making its full portfolio of CT tubes for GE and Siemens CT scanners available once again.Click to learn more



“DaVita ignored many red flags that preceded the loss of life of these three patients and many others,” said lead trial attorney Rob Carey of Hagens Berman. “It is our mission now to fight for the rights of those who lost their lives due to DaVita’s abhorrent oversight and negligence.”

DaVita will appeal the case, according to Reuters.

“Our first priority is the safety of our patients,” DaVita said, according to news agency. “Our clinical outcomes – among the best in the industry – demonstrate our commitment to providing the highest level of care.”

In 2012, FDA put out a Class 1 recall for GranuFlo, warning clinicians that the excess acetate in GranuFlo could lead to high bicarbonate levels and metabolic alkalosis, which can lead to cardiopulmonary arrest and death. GranuFlo, made by Fresenius Medical Care, helps remove waste products and maintain proper pH balance in a patient’s blood, according to Reuters.

After the FDA recall, in 2013, Hagens Berman filed wrongful death suits charging that there were “several things DaVita could and should have done, but did not do, to protect its patients.” According to the legal complaints, the company “failed to inspect and review the composition of GranuFlo and notice changes,” and in addition, DaVita “should have noticed a significant upswing overall in bicarbonate blood levels when patients returned for dialysis treatments.”

The firm’s filings also state that the company should also have spotted the “uptick in reports of death and complications.”

The relationship between heart problems and dialysis was looked at in late 2016, researchers used MR to gain insight on the relationship.

In a University of Nottingham study, appearing in the Journal of the American Society of Nephrology, the scientists showed that the treatment could reduce blood flow and lead to permanent heart damage, whether the patients were on standard hemodialysis (HD) or hemodiafiltration (HDF).
  Pages: 1 - 2 >>

Business Affairs Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2018 DOTmed.com, Inc.
ALL RIGHTS RESERVED